TradingKey

关于 Blueprint Medicines Corp 公司

Blueprint Medicines Corporation 是一家全球精准治疗公司，正在过敏/炎症和肿瘤/血液学两个领域发明改变生命的药物。该公司向美国和欧洲的患者提供其获批的药物，包括 AYVAKIT/AYVAKYT (avapritinib) 和 GAVRETO (pralsetinib)，并在全球范围内推进针对系统性肥大细胞增多症 (SM)、肺癌、乳腺癌和其他基因组定义的癌症以及癌症免疫疗法的多个项目。该公司的产品线还包括 Elenestinib (BLU-263) (KIT)、AYVAKIT (avapritinib) (KIT)、野生型 KIT 研究项目、GAVRETO (pralsetinib) (RET)、BLU-945 (EGFR)、BLU-525 (EGFR)、BLU-451 (EGFR 外显子 20 插入)、BLU-222 (CDK2)、AYVAKIT (PDGFRA)、GAVRETO (RET)、BLU-222 (CDK2) 和 BLU-852 (MAP4K1)。该公司正在开发一种口服、有效且高选择性的试验性 KIT 抑制剂 Elenestinib (BLU-263)，用于治疗惰性 SM 和其他肥大细胞疾病。

公司简介

公司代码BPMC

公司名称Blueprint Medicines Corp

上市日期Apr 30, 2015

CEOMs. Kathryn D (Kate) Haviland

员工数量649

证券类型Ordinary Share

年结日Apr 30

公司地址45 Sidney Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编02139

电话16173747580

网址https://www.blueprintmedicines.com/

公司代码BPMC

上市日期Apr 30, 2015

CEOMs. Kathryn D (Kate) Haviland

公司高管

名称

名称/职务

职务

持股

持股变动

Ms. Kathryn D (Kate) Haviland

President, Chief Executive Officer

73.23K

+22.22%

Dr. Fouad Namouni, M.D.

President - Research and Development

31.96K

+33.54%

Ms. Christina Rossi

Chief Operating Officer

19.39K

-19.00%

Mr. Percy H. Carter, Ph.D.

Chief Scientific Officer

16.43K

-13.93%

Mr. Michael Landsittel

Chief Financial Officer

13.43K

-68.90%

Ms. Ariel Hurley, CPA

Senior Vice President - Finance, Principal Accounting Officer

11.89K

--

Mr. Michael J. Tolpa

Director

--

Ms. Debra Durso-Bumpus

Chief People Officer

--

Dr. Philina Lee, Ph.D.

Chief Commercial Officer

--

-100.00%

Ms. Jenna Cohen

Vice President and Head, Investor Relations

--

名称

名称/职务

职务

持股

持股变动

Ms. Kathryn D (Kate) Haviland

President, Chief Executive Officer

73.23K

+22.22%

Dr. Fouad Namouni, M.D.

President - Research and Development

31.96K

+33.54%

Ms. Christina Rossi

Chief Operating Officer

19.39K

-19.00%

Mr. Percy H. Carter, Ph.D.

Chief Scientific Officer

16.43K

-13.93%

Mr. Michael Landsittel

Chief Financial Officer

13.43K

-68.90%

Ms. Ariel Hurley, CPA

Senior Vice President - Finance, Principal Accounting Officer

11.89K

--

收入明细

单位: USD更新时间: 4月6日周日

FY2024Q3

FY2024Q2

FY2024Q1

业务USD

名称

营收

占比

Product revenue

128.18M

100.00%

Collaboration, license and other revenue

1.00K

0.00%

地区USD

名称

营收

占比

United States

113.13M

88.26%

Rest of the world

15.05M

11.74%

业务

地区

业务USD

名称

营收

占比

Product revenue

128.18M

100.00%

Collaboration, license and other revenue

1.00K

0.00%

股东统计

更新时间: 8月13日周三

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.90%

T. Rowe Price Associates, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

7.29%

Avoro Capital Advisors LLC

5.95%

Wellington Management Company, LLP

4.75%

其他

63.83%

持股股东

占比

The Vanguard Group, Inc.

9.90%

T. Rowe Price Associates, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

7.29%

Avoro Capital Advisors LLC

5.95%

Wellington Management Company, LLP

4.75%

其他

63.83%

股东类型

持股股东

占比

Investment Advisor

47.91%

Investment Advisor/Hedge Fund

37.26%

Hedge Fund

10.81%

Research Firm

3.15%

Sovereign Wealth Fund

1.10%

Individual Investor

0.93%

Bank and Trust

0.80%

Venture Capital

0.77%

Pension Fund

0.60%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

701

68.81M

106.41%

-3.22M

2025Q1

702

71.75M

110.98%

-1.27M

2024Q4

657

69.17M

108.25%

-2.83M

2024Q3

644

67.12M

105.97%

-7.85M

2024Q2

622

68.23M

108.95%

-6.94M

2024Q1

615

67.81M

110.73%

-5.62M

2023Q4

612

65.87M

108.35%

-10.02M

2023Q3

602

66.47M

109.56%

-7.64M

2023Q2

614

65.78M

108.78%

-8.60M

2023Q1

625

65.63M

109.42%

-10.28M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

6.63M

10.25%

-134.36K

-1.99%

Mar 31, 2025

T. Rowe Price Associates, Inc.

5.35M

8.28%

-266.46K

-4.74%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.89M

7.57%

-106.17K

-2.12%

Mar 31, 2025

Avoro Capital Advisors LLC

3.85M

5.95%

+2.67M

+224.89%

Mar 31, 2025

Wellington Management Company, LLP

3.07M

4.75%

-1.21M

-28.22%

Mar 31, 2025

State Street Global Advisors (US)

2.68M

4.15%

+183.91K

+7.36%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.52M

2.35%

+32.55K

+2.18%

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

1.30M

2.01%

+605.78K

+86.91%

Mar 31, 2025

Macquarie Investment Management

1.29M

1.99%

+27.92K

+2.22%

Mar 31, 2025

AllianceBernstein L.P.

1.20M

1.85%

+58.22K

+5.12%

Mar 31, 2025

持股ETF

更新时间: 8月6日周三

机构名称

占比

ProShares Merger ETF

3.21%

AltShares Event-Driven ETF

1.43%

ProShares Ultra Nasdaq Biotechnology

0.92%

Goldman Sachs Future Health Care Equity ETF

0.84%

Hypatia Women CEO ETF

0.73%

First Trust Mid Cap Growth AlphaDEX Fund

0.58%

iShares Russell 2000 Growth ETF

0.54%

WisdomTree BioRevolution Fund

0.49%

SoFi Next 500 ETF

0.45%

JPMorgan Fundamental Data Science Small Core ETF

0.43%

ProShares Merger ETF

占比3.21%

AltShares Event-Driven ETF

占比1.43%

ProShares Ultra Nasdaq Biotechnology

占比0.92%

Goldman Sachs Future Health Care Equity ETF

占比0.84%

Hypatia Women CEO ETF

占比0.73%

First Trust Mid Cap Growth AlphaDEX Fund

占比0.58%

iShares Russell 2000 Growth ETF

占比0.54%

WisdomTree BioRevolution Fund

占比0.49%

SoFi Next 500 ETF

占比0.45%

JPMorgan Fundamental Data Science Small Core ETF

占比0.43%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Blueprint Medicines Corp

129.460USD

Blueprint Medicines Corp

129.460

概览

公司

财务